BoostmybodyYou decide

For a closer look

Research Library

Read what researchers wanted to find out and what it means in everyday words. Open the details if you want to see how a study was done. The product pages have a shorter explanation.

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Showing research linked to Ipamorelin.

Back to the short explanation

2 studies found

Research context

A short hormone pulse

Healthy men in a short intravenous research study

What did they want to find out?

What happened to ipamorelin and GH levels in the blood?

What did researchers observe?

Researchers observed a brief GH rise and measured how quickly ipamorelin left the bloodstream.

What does this mean for you?

A lab marker can change without improving strength, sleep or everyday recovery.

What we still do not know

Short exposure does not answer repeated-use or long-term safety questions.

Show study details

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Pharmaceutical Research · 1999

How it was studied

Short human pharmacokinetic and hormone-response study. Five intravenous exposure levels with eight healthy men at each level.

Study finding

Ipamorelin produced a brief GH pulse and had a reported terminal half-life of about two hours.

Study limitations

This measured substance levels and growth hormone, not strength, sleep or recovery. It does not establish long-term safety or equivalence of retail formulations.

Who is behind the study?

Identified authors
J. V. Gobburu, H. Agersø, W. J. Jusko, L. Ynddal
Funding and involvement
Not confirmed from the accessed source sections.
Disclosed interests and verification limits
The publisher lists Agersø and Ynddal at Novo Nordisk and Gobburu and Jusko at SUNY Buffalo. Company coauthorship is verified; formal conflict declarations were not confirmed.

Terms explained

GH
Growth hormone, one of the body's signaling hormones.
Half-life
The time for a measured substance level to fall by about half; not a recommended use interval.

Read the source and its limitations. A reference does not automatically validate a commercial product.

Read the source
Research context

A real comparison with placebo

Patients recovering from bowel surgery

What did they want to find out?

Did ipamorelin help people tolerate a solid meal sooner?

What did researchers observe?

The numerical difference favored ipamorelin, but was not statistically convincing.

What does this mean for you?

A lower number alone does not show a reliable treatment effect.

What we still do not know

This surgical study does not answer bodybuilding or sleep claims; no significant difference does not prove the treatments equal.

Show study details

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

International Journal of Colorectal Disease · 2014

How it was studied

Multicenter double-blind randomized placebo-controlled phase-2 trial. 117 bowel-surgery patients enrolled; 114 in safety and modified intention-to-treat analyses.

Study finding

Median time to tolerating a solid meal was 25.3 versus 32.6 hours with placebo; the difference was not statistically significant (P=0.15).

Study limitations

No significant difference in key or secondary efficacy outcomes. Adverse events occurred frequently in both surgical groups; this is not proof of safety equivalence or sports benefits.

Who is behind the study?

Identified authors
David E. Beck, W. Brian Sweeney, Martin D. McCarter, Ipamorelin 201 Study Group
Funding and involvement
Helsinn Therapeutics (US), Inc. supported the study, gave institutional grants and supported manuscript development.
Disclosed interests and verification limits
Authors declare no financial or proprietary conflicts; they separately disclose institutional Helsinn grants. The Curry Rockefeller Group provided editorial/production assistance; sponsor publication-control terms are unknown.

Terms explained

Placebo
A comparison treatment without the tested active substance.
Statistically significant
Evidence that a difference is difficult to explain by chance under a study's assumptions; it does not automatically mean a useful benefit.

Read the source and its limitations. A reference does not automatically validate a commercial product.

Read the source